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MET inhibitors have shown activity in non-small-cell lung cancer patients
(NSCLC) with MET amplification and exon 14 skipping (METDex14).
However, patient stratification is imperfect, and thus, response rates have
varied widely. Here, we studied MET alterations in 474 advanced NSCLC
patients by nCounter, an RNA-based technique, together with next-genera-
tion sequencing (NGS), fluorescence in situ hybridization (FISH), immuno-
histochemistry (IHC), and reverse transcriptase polymerase chain reaction
(RT–PCR), exploring correlation with clinical benefit. Of the 474 samples
analyzed, 422 (89%) yielded valid results by nCounter, which identified 13
patients (3%) with METDex14 and 15 patients (3.5%) with very-high
MET mRNA expression. These two subgroups were mutually exclusive,
displayed distinct phenotypes and did not generally coexist with other dri-
vers. For METDex14, 3/8 (37.5%) samples positive by nCounter tested
negative by NGS. Regarding patients with very-high MET mRNA, 92%
had MET amplification by FISH and/or NGS. However, FISH failed to
identify three patients (30%) with very-high MET RNA expression, among
which one received MET tyrosine kinase inhibitor treatment deriving
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clinical benefit. Our results indicate that quantitative mRNA-based tech-
niques can improve the selection of patients for MET-targeted therapies.
1. Introduction
Aberrant activation of the mesenchymal–epithelial
transition (MET) gene has recently emerged as an
actionable target, particularly in non-small-cell lung
cancer (NSCLC) [1,2]. Multiple molecular mechanisms
including amplification, point mutations, alternative
splicing, and protein overexpression [3,4] can lead to
abnormal MET activation, which increases cell prolif-
eration, survival, invasion, and metastasis. MET
amplification has been described in 1–6% of newly
diagnosed NSCLC tumors and constitutes a frequent
mechanism of acquired resistance in EGFR-mutant
(EGFR-mut) NSCLC patients treated with tyrosine
kinase inhibitors (TKI) [5]. MET exon 14 alterations
in donor and acceptor splicing sites—including point
mutations, indels, and whole-exon deletions—lead to
the exclusion (skipping) of MET exon 14 at the RNA
level (METΔex14), which has been described in 3–4%
of patients with advanced NSCLC [6–8].
Amplification of the MET gene in NSCLC and muta-
tions leading to METΔex14 were first reported in 2005
and 2006, respectively [9,10], while two seminal works
published in 2015 identified METΔex14 as a potential
therapeutic target in advanced NSCLC [11,12]. Since
then, several trials have evaluated the efficacy of MET
inhibitors in patients with METΔex14 and MET ampli-
fication [13–17], with response rates varying widely
across the different studies. Capmatinib is the first MET
inhibitor that has gained recent Food and Drug Admin-
istration approval for the treatment of advanced
NSCLC with METΔex14 [18], and novel mechanisms of
resistance have meanwhile started to emerge [19].
The most frequent technologies used to assess MET
gene copy number variations in the clinical setting are
fluorescence in situ hybridization (FISH) and next-gen-
eration sequencing (NGS), whereas for METΔex14
detection, both NGS and reverse transcription poly-
merase chain reaction (RT–PCR) are commonly used
[6,7,13,14,20–24]. However, the optimal method(s) and
the more adequate thresholds for stratification are not
yet defined. The controversies around MET testing
[25] have been complicated by the small number of
comprehensive studies on MET status in advanced
NSCLC and the fact that most reports evaluating the
performance of different techniques have focused on a
single MET alteration.
The NanoString nCounterTM Analysis System is a
high-throughput, quantitative transcript-based hybri-
dization technology that allows for the simultaneous
analysis of the expression of hundreds of target genes
[26] and can be easily incorporated in the routine
molecular testing workflow of tumor samples [27].
Although nCounter has been used to determine some
MET alterations in particular types of tumors [28–30],
it has never been employed for MET testing in
NSCLC. In the previous studies, we demonstrated that
this methodology can identify relevant gene rearrange-
ments in advanced NSCLC [27,31]. Here, we aimed to
determine whether nCounter could improve the char-
acterization of clinically relevant MET alterations. To
this end, we screened a large cohort of NSCLC
patients and compared the nCounter results with those
obtained by standard techniques. Our results indicate
that multiplex, RNA-based techniques such as nCoun-
ter have the potential to become the technology of
choice to select patients for MET-targeted therapies.
2. Materials and methods
2.1. Patients, samples, and cell lines
A total of 474 formalin-fixed, paraffin-embedded
(FFPE) tumor samples from patients with NSCLC were
tested to identify MET alterations. Samples were col-
lected from 10 participating hospitals (Supporting Infor-
mation) with prior full informed patient consent and
approval from the corresponding ethical committees.
All advanced NSCLC patients arriving to our institu-
tions and having biopsies available with sufficient tumor
tissue were offered to participate in the study, which
Abbreviations
FISH, fluorescence in situ hybridization; HS, histoscore; IHC, immunohistochemistry; nC, nCounter; NGS, next-generation sequencing;
NSCLC, non-small-cell lung cancer; RT–PCR, reverse transcription polymerase chain reaction.
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was conducted in accordance with the principles of the
Declaration of Helsinki. FFPE slides (4 µm) were
obtained by standard procedures and stained with
hematoxylin and eosin. A pathologist determined the
tumor area and evaluated the percentage of tumor infil-
tration. RNA was extracted with a high purity FFPE
RNA isolation kit (Roche, Mannheim, Germany), while
the GeneRead DNA FFPE Kit or the QIAamp DNA
FFPE Tissue Kit (Qiagen, Hilden, Germany) was used
for DNA extraction from FFPE samples, according to
the manufacturer’s instructions. DNA and RNA con-
centrations were measured by Qubit (Thermo Fisher
Scientific, Waltham, MA, USA). Three cell lines
(Hs746T, PC9, and E98) were used for validation pur-
poses. The Hs746T cell line, harboring METDex14, was
purchased from the American Type Culture Collection.
E98 is a patient-derived astrocytoma cell line with
amplification of MET gene. EGFR-mut PC9 cells were
obtained from F. Hoffman-La Roche Ltd (Basel,
Switzerland) with the authorization of Dr. Mayumi
Ono (Kyushu University, Fukuoka, Japan). All cell
lines were cultured in RPMI medium with 10% fetal
bovine serum under standard conditions and counted
after trypsinization. Pellets from a minimum of five T-
75 flasks were used to generate FFPE blocks.
2.2. FISH and immunohistochemistry (IHC)
FISH for MET was performed with the ZytoLight
SPEC MET/centromere 7 (MET/CEP7) Dual Color
Probe (ZytoVision, Bremerhaven, Germany) according
to manufacturer’s instructions. Three positivity criteria
for MET amplification were used as follows: (a) a ratio
(r) MET/CEP7 ≥ 2; (b) gene copy number (GCN) per
cell ≥ 6; (c) ≥ 5 copies in ≥ 50% of cells; (d) or ≥ 15
copies in > 10% tumor cells. These three criteria have
been employed for patient stratification in clinical trials
of anti-MET therapies (Table S1). Immunostaining was
performed with MET SP44 clone (Roche) on a Bench-
Mark ULTRA automated tissue staining system (Ven-
tana Medical Systems, Tucson, AZ, USA). Two
different cutoff points for IHC positivity were consid-
ered: (i) membrane intense staining (3+) in ≥ 50% of the
tumor cells and (ii) histoscore (HS) ≥ 220.
2.3. NGS sample preparation, sequencing run,
and data processing
DNA NGS was performed with the GeneRead
QIAact Lung DNA UMI Panel (Qiagen) or Oncomi-
neTM Solid Tumour (OST) DNA Panel (Thermo
Fisher Scientific), according to the manufacturer’s
instructions (Table S2). Both panels target genes
frequently altered in lung cancer, including DNA alter-
ations at exons 13–15 of MET and the surrounding
intronic regions. The GeneRead panel can also detect
amplifications in five genes. For the GeneRead panel,
up to 40 ng of purified DNA was used as a template.
Clonal amplification was performed on 625 pg of
pooled libraries, and, following bead enrichment, the
GeneReader instrument was used for sequencing.
RNA-NGS was performed with the GeneRead
QIAact Lung RNA Fusion UMI Panel (Qiagen)
according to the manufacturer’s instructions. This panel
targets a fusion-specific and splicing variants (Table S2),
including METDex14. The GeneRead QIAact Lung
RNA Fusion UMI Panel is designed to enrich selected
fusion targets starting with 100 ng of total RNA. After
target enrichment and library preparation, clonal ampli-
fication was performed using 625 pg of pooled libraries,
and, following bead enrichment, the GeneReader instru-
ment was used for sequencing.
Qiagen Clinical Insight Analyze (QCI-A) software was
employed to align the read data and call sequence vari-
ants, which were imported into the Qiagen Clinical
Insight Interpret (QCI-I) web interface for data inter-
pretation and generation of final custom report. In the
case of the OST panel, 10 ng of purified DNA was used
as a template. Libraries were pooled at 20 pM and, fol-
lowing ion spheres, sequenced using the Ion Personal
Genome Machine (Thermo Fisher Scientific). The Ion
Reporter Server (Thermo Fisher Scientific) was used to
align the read data to the human reference genome and
call sequence variants. The MET gene copy numbers by
NGS were assessed using the QCI-A and QCI-I soft-
ware. Copy numbers provided by QCI-I were selected
according to the tumor infiltration of the sample, as
assessed by an expert pathologist. The GCN ≥ 6 was
chosen as a threshold based on the previous experience
of our laboratory. During the validation of the NGS
panel prior to its implementation in the clinical setting,
this threshold had been found to show the highest corre-
lation with FISH MET/CEP7 > 2.
2.4. RT–PCR analysis for METDex14 transcripts
RNA was converted to cDNA using M-MLV retro-
transcriptase (Thermo Fisher Scientific) and oligo-dT
primers, and METDex14 was amplified using HotStart
Taq polymerase (Qiagen) in a 20 µL reaction and visu-
alized in agarose gels. Primers used were located in
exons 13 and 15, sequences were as follows: forward
(exon 13) 50-TTTTCCTGTGGCTGAAAAAGA-30
and reverse (exon 15) 50-GGGGACATGTCTGTCA-
GAGG-30. Amplification generated a 246-bp band for
wild-type (wt) MET RNA and a 106-bp band for
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METDex14. Positive samples were confirmed by bidi-
rectional Sanger sequencing of RT–PCR products,
using the big-dye 3.1 sequencing kit (Applied Biosys-
tems, Waltham, MA, USA).
2.5. nCounter analysis
Total RNA was hybridized with a custom-designed
mixture of biotinylated capture tags and fluorescently
labeled reporter probes (Elements Chemistry) that
included, among others, probes for MET-wt and
METDex14 target sequences. Detailed sequence infor-
mation for the MET gene target regions is provided in
Table S3. The codeset also included probes for house-
keeping genes (actin beta, ACTB; proteasome 26S sub-
unit ATPase 4, PSMC4 and mitochondrial ribosomal
protein L19, MRPL19), positive and negative controls.
All processes of hybridization, capture, cleanup, and
digital data acquisition were performed with nCounter
Prep Station and Digital Analyzer (NanoString
Technologies, Seatle, WA, USA) according to the
manufacturer’s instructions. Reporter counts were col-
lected with the NSOLVER analysis software version 2.6.
Samples were considered not evaluable if the geometri-
cal mean (geomean) of counts corresponding to the
housekeeping genes was lower than 100. Counts from
MET probes were normalized in two steps, as
described [31], and subjected to a logarithmic transfor-
mation to obtain the so-called log-MET expression
values. Two cutoff values were used for log-MET
results; (a) the mean plus standard deviation (SD) was
used to define cases with moderately (mod.)-elevated
MET mRNA, (b) the mean plus two SD for very-high
MET mRNA levels. Regarding METDex14 testing,
log-ratios were obtained dividing the normalized
counts of the METDex14 probe by the normalized
counts for the MET-wt probe. The cutoff for MET-
Dex14 positivity was established as the average log-ra-
tio of the sample cohort plus 2 SD. Samples with no
counts for the METDex14 probe were directly consid-
ered negative.
2.6. Validation of nCounter for detection of MET
alterations
Using frozen pellets from Hs746T or E98 cells, we
found that 5000 cells and 25 ng of RNA were suffi-
cient for successful detection of spliced transcripts or
very-high MET mRNA levels, respectively. In con-
trast, pellets containing 500 000 of PC9 cells (MET-
wt) tested negative. Next, using FFPE blocks pre-
pared by spiking different numbers of MET-depen-
dent cells (Hs746T and E98) in a suspension of PC9
cells, we established that 1 mm2 of a 4-µm section
with a minimum of 10% of Hs746T cells was
required for METDex14 detection, whereas 30% of
E98 cells were needed to detect high levels of MET
mRNA expression by nCounter. In similar experi-
ments, RT–PCR detected METDex14 mRNA in mix-
tures with 0.1% mutant tumor cells. Finally, we
performed repeatability studies using FFPE tumors
from advanced NSCLC patients. In the case of
METDex14 detection by nCounter, four positive and
20 negative samples were analyzed in two indepen-
dent experiments showing a 100% concordance.
Regarding MET mRNA expression, 29 samples run
in two independent experiments revealed concordant




A total of 474 FFPE NSCLC tumor samples were pro-
filed using nCounter. Among them, 52 (11%) had geo-
mean of housekeeping gene counts below 100 and
were excluded from the study. The remaining 422
evaluable samples, corresponding to 405 patients, were
mostly stage IIIB/IV adenocarcinomas (Table S4,
Table 1). Four additional techniques were used in dif-
ferent subsets of samples to validate the MET status
determined by nCounter. Copy number alterations
were analyzed by FISH and/or NGS, METDex14 tran-
scripts by RT–PCR or DNA-based NGS, and protein
expression by IHC (Fig. 1).
3.2. Detection of METΔex14 mRNA by nCounter
in clinical samples
For each of the 422 samples evaluable, we calculated
the log-ratio of the normalized nCounter counts corre-
sponding to the METDex14 vs. the MET-wt probes. A
sample was considered positive if the log-ratio was
above a threshold value, established as the mean plus
two times the SD of all samples analyzed (Fig. 2A).
The METDex14/ MET-wt log-ratios in our cohort
showed a bimodal distribution with the cutoff value
separating the two populations (Fig. 2B). A total of 13
METDex14-positive patients (3%) were identified, with
a majority of nonsmoking females and a median age
of 70 years (Table 1). Of them, five were treated with
MET-TKIs and showed partial responses (N = 4) or
stabilization of the disease (N = 1) by RECIST criteria
(Fig. 2C).
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Eight of the 13 METDex14-positive cases could be
submitted to DNA-based NGS. Mutations affecting
exon 14 splicing sites were detected in five of them
(62.5%), mainly deletions in the acceptor splice-site
region (Table S5). Regarding other alterations, two
patients showed PIK3CA mutations while concomitant
MET amplification by GCN (6–10) was identified in
only one sample (20%). However, this case was nega-
tive (< 2) by MET/CEP7 ratio. Sufficient tissue to per-
form MET IHC was available for four of the 13
patients; MET staining was intermediate in three cases
and strong in one (Fig. 2C).
3.3. Quantification of MET mRNA expression
levels by nCounter in clinical samples
The raw counts of the MET probes for each sample
were transformed into logarithmic normalized data
(log-MET). According to our classification algorithm
(see Section 2), 15/422 samples (3.5%) presented very-
high MET mRNA levels (Fig. 3) and 36/422 samples
(8.5%) mod-elevated MET mRNA levels by nCounter
(Fig. 4). In contrast to the log-ratio, the distribution
of the log-MET values was unimodal, although a Kol-
mogorov–Smirnov test revealed a significant deviation
from normality (P = 0.001; Fig. 3A,B). Most of the 15
patients with very-high MET mRNA levels were
males, former or current smokers with a median age
of 58 years (Table 1). They invariably showed very
strong IHC staining (≥ 220), tested negative for MET-
Dex14 by nCounter and 92% (11/12) had MET ampli-
fication by FISH or NGS (Fig. 3C). Finally, among
the 9 baseline patients with very-high MET, no other
driver was detected in seven (77.8%). Five patients
with very-high MET mRNA were treated with MET-
TKIs, all of them showed partial responses by
RECIST criteria. Interestingly, one was negative by
FISH (Fig. 3C).
Regarding the 36 cases with mod-elevated MET
mRNA levels, we found comparable numbers of males
and females, smokers, and never smokers with median
age of 64 years (Table 1). The majority (19/27) of
baseline samples with mod-elevated MET and geno-
typing data available harbored concurrent genetic
alterations, being mutations in KRAS proto-oncogene
GTPase (KRAS) and epidermal growth factor receptor
(EGFR), fusions in ALK receptor tyrosine kinase
(ALK), and METDex14 the most prevalent (N = 4
each; Fig. 4).
3.4. Comparison of METDex14 nCounter results
with RT–PCR and DNA-based NGS in clinical
samples
The concordance of nCounter with RT–PCR and
DNA-based NGS for the detection of METDex14 is
shown in Table S6, together with the corresponding
values of specificity, sensitivity, and Cohen’s kappa.
We observed a substantial agreement when comparing
nCounter vs. DNA-based NGS, with a 98.5% concor-
dance rate (CI = 95.6–99.5, Cohen’s kappa 0.76) and
only three discordant samples, all of them positive by
nCounter and negative by DNA-based NGS. Regard-
ing nCounter and RT–PCR, there was a fair agree-
ment (90.2%, CI = 83.3–94.4, Cohen’s kappa 0.65)
and all the discordant cases (N = 11) were negative by
nCounter and positive by RT–PCR. Six of those dis-
cordant samples had been analyzed by DNA-based
NGS; mutations associated with METDex14 were not
detected in any case (Fig. S1). Five of them with
remaining material were further investigated by an
Table 1. Characteristics of all patients with valid results, patients
positive for METDex14 by nCounter, and patients with very-high



















4 (30.8) 10 (66.7) 19 (52.8)
Female 146
(36.1)
9 (69.2) 5 (33.3) 16 (44.4)
Unknown 11 (2.7) 0 (0) 0 (0) 1 (2.8)
Age at diagnosis
Median 63 70 58 64




5 (38.5) 1 (6.7) 15 (41.7)
Former 134
(33.1)
2 (15.4) 6 (40.0) 7 (19.4)
Current 115
(28.4)
0 (0) 6 (40.0) 9 (25.0)
Unknown 79
(19.5)




3 (23.1) 2 (13.3) 4 (11.1)
Baseline 294
(72.6)
10 (76.9) 9 (60.0) 27 (75.0)
Baseline and
progression





0 4 (27.8) 5 (13.9)
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orthogonal RNA-based NGS and all tested negative
for METDex14 skipping transcripts. Finally, we sys-
tematically sequenced the 106 bp cDNA band, corre-
sponding to the METDex14 mRNA, obtained in RT–
PCR-positive samples. No differences were observed
between concordant and discordant samples, being the
base sequence of the exon 13–exon 15 junction identi-
cal in all cases to the sequence described in the litera-
ture [9].
3.5. Comparison of MET expression levels by
nCounter with MET amplification by FISH and
NGS in clinical samples
A total of 40 samples had evaluable data by FISH and
nCounter. Three different criteria for MET positivity
were used for FISH evaluation (see Section 2). A mod-
erate to substantial agreement was observed if the
nCounter very-high cutoff was employed, with the
highest agreement for the FISH ratio MET/CEP7 ≥ 2
(concordance rate 92.5%, Cohen’s kappa 0.778;
Table S7). The only three discordant samples were
positive by nCounter and negative by FISH. Two of
them had remaining material available and were sub-
mitted to RNA-based NGS, testing negative for
known MET gene fusions. If the nCounter mod-
elevated cutoff was selected, the agreement was only
fair with any of the three FISH amplification criteria,
with concordance rates of 50%-70% and Cohen’s
kappa 0.185–0.410 (Table S8).
DNA-based NGS with the GeneRead platform,
which can detect amplifications in several genes, was
performed in 80 samples with nCounter data. MET
amplification by DNA-based NGS showed an almost
perfect agreement with very-high MET mRNA levels,
with a Cohen’s kappa of 0.886 and a 97.5% concor-
dance rate (Table S7). The only two discordant sam-
ples were MET amplified by NGS but did not show
very-high MET mRNA expression levels by nCounter.
In contrast, if mod-elevated MET mRNA levels were
employed, the agreement with MET amplification by
NGS was significantly worse (Cohen’s kappa 0.494)
and the 14 discordant cases had moderately elevated
MET mRNA but did not show copy number gains
(Table S8).
3.6. Comparison of MET expression levels by
nCounter and IHC in clinical samples
Ninety-one samples were used to perform a compara-
tive study of IHC vs. nCounter for the quantification
of MET expression levels. Among these 91 samples, 34
Fig. 1. Flowchart of the study. FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; NGS, next-generation sequencing;
NSCLC, non-small-cell lung cancer; RT–PCR, reverse transcription polymerase chain reaction.
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showed very strong MET by IHC (HS ≥ 220), 19
intermediate (HS 100–220), 21 weak (HS 50–99), and
17 were very weak-negative (HS < 50). In general, a
fair agreement was observed between IHC and nCoun-
ter expression levels, with IHC positivity observed
among cases with both mod-elevated and very-high
mRNA levels (Tables S7 and S8).
3.7. Expression levels of MET mRNA in clinical
samples with driver alterations
Finally, we compared MET mRNA levels by nCounter
in patients harboring different drivers (Fig. S2). Base-
line MET expression by nCounter was found to be
significantly increased in samples with MET amplifica-
tion, METDex14, and BRAF mutations (P < 0.05 in a
Mann–Whitney U test), but not in cases with EGFR
and KRAS mutations or ALK rearrangements. Next,
we compared MET mRNA expression in samples at
baseline vs. progression. Overall, there were no signifi-
cant differences in log-MET values between the 306
basal and the 52 progression samples included in the
study. When classified by drivers, we did observe a sig-
nificant increase in MET mRNA levels in tumors at
progression vs. baseline only in EGFR-mu tant sam-
ples. However, a subpopulation of samples at progres-
sion with high MET mRNA expression was apparent
not only in EGFR mutant, but also in ALK-positive
rebiopsies.
4. Discussion
In this study, we comprehensively characterized the




Fig. 2. Detection of METDex14 by nCounter. (A) METDex14/MET-wt normalized counts obtained by nCounter, expressed as log-ratios. Only
samples with detectable counts for METDex14 are plotted. The line indicates the cutoff for positivity (mean + 2SD). (B) Plot showing the
bimodal distribution of METDex14/MET-wt nCounter log-ratios in the cohort. The line indicates the cutoff for positivity (mean + 2SD). (C)
Heatmap displaying METDex14-positive samples by nCounter (N = 13) and correlative results for RT–PCR, mRNA expression (nC), MET
mutations (NGS), copy number alterations (FISH or NGS), immunohistochemistry (IHC), and other co-occurring driver alterations. Patient
numbers are shown in the top row. FISH, fluorescence in situ hybridization; HS, histoscore; IHC, immunohistochemistry; Mod, moderately; N/A
nonavailable data; nC, nCounter; NGS, next-generation sequencing; PR, partial response; RT–PCR, reverse transcription polymerase chain
reaction; SD, stable disease. [Correction added on 9 December 2020, after first online publication: Missing details in the figure were amended.]
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and exon 14 skipping—in a large cohort of 474
NSCLC samples using of a RNA-based technology
(nCounter; Fig. 5) and we systematically compared the
results with other currently available methods for
MET testing. We also propose an algorithm for the
selection of patients to be considered for MET-TKI
treatment, based on the RNA-based results.
Our prevalence of METDex14 by nCounter (3%) is
in line with the literature [6,7], particularly when other
RNA-based techniques such as RNA sequencing or
quantitative RT–PCR were used [32,33]. In our series,
all cases positive for METDex14 transcripts by nCoun-
ter (N = 13) were also detected by RT–PCR; however,
a large subset of samples positive by RT–PCR
(N = 11) tested negative by nCounter. Five of these
discordant samples could be submitted to an orthogo-
nal RNA-based NGS, which confirmed them as
negative. In addition, most of them were found to har-
bor known drivers, particularly KRAS. Although RT–
PCR is used in some laboratories to identify
METΔex14 transcripts, these results suggest that it
might not be the most adequate technique for this pur-
pose. Low level of METDex14 transcripts can emerge
by splicing ‘mistakes’ in the cell without translating in
any genomic alteration with oncogenic relevance [34–
36]. These splicing ‘mistakes’ would test positive by
mRNA amplification (RT–PCR), but not by nCoun-
ter, DNA-, or RNA-based NGS.
DNA-based NGS using commercially available pan-
els is also employed to determine METΔex14. How-
ever, this technique has been reported to detect only
63% of literature-described splicing mutations associ-
ated with METDex14 [37], and reanalysis of 232 pan-
negative samples by DNA-based NGS using RNA
A C
B
Fig. 3. Quantification of MET mRNA expression levels by nCounter. (A) MET normalized counts obtained by nCounter, expressed as log-
MET. The cutoff values for moderately elevated MET mRNA expression (mean + SD) and very-high MET mRNA expression (mean + 2SD)
are indicated with lines. (B) Plot showing the unimodal distribution of log-MET in the sample cohort. (C) Heatmap displaying samples with
very-high levels of MET mRNA expression by nCounter (N = 15) and corresponding results for METDex14 (nC), RT–PCR, MET mutations
(NGS), copy number alterations (FISH or NGS), immunohistochemistry (IHC), and other co-occurring driver alterations. Patient numbers are
shown in the top row. FISH, fluorescence in situ hybridization; GCN, gene copy number; HS, histoscore; IHC, immunohistochemistry; Mod,
moderately; N/A nonavailable data; nC, nCounter; NGS, next-generation sequencing; PR, partial response; RT–PCR, reverse transcription
polymerase chain reaction; SD, stable disease
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sequencing revealed six (2.5%) METDex14-positive
cases previously missed [33]. In our cohort, among the
eight tumors with METDex14 by nCounter that were
submitted to DNA-based NGS, three (37.5%) tested
negative for mutations associated with METDex14
splicing sites. One of these discordant patients was
treated with a MET-TKI and derived clinical benefit
(Patient 7, Fig. 2C). It is probable that at least some
of these cases involved large genomic deletions that
are difficult to detect on DNA-based NGS assays [32].
Therefore, our results confirm that DNA-based tech-
niques might underestimate the detection of MET-
Dex14 alterations.
Consistent with other studies [6,7,13–15,38], most of
the MET Δex14 patients detected by nCounter were
elderly females, with a considerable proportion of
never smokers (38%; Table 1). In addition, as previ-
ously reported, METΔex14 rarely coexisted with other
drivers and was associated with moderate but not high
MET expression by IHC [6,38]. Finally, we only
detected MET amplification by FISH or NGS in one
(14%) of the METΔex14-positive cases, compared to
the 8–30% reported in the literature using different
detection techniques and thresholds [6,7,13,15,17]. The
significance of MET amplification in the context of
METΔex14 alterations is unclear, but recent data from
a prospective trial [15–17] indicate that it does affect
response to MET-TKIs, endorsing METΔex14 as a
truly separate driver in NSCLC. Indeed, all
METΔex14 patients in our cohort treated with MET-
TKIs derived clinical benefit, regardless of MET
amplification status (Patients 2, 3, 4, 6, 7; Fig. 2C).
In addition to the presence of METΔex14 tran-
scripts, we analyzed wt MET mRNA and could iden-
tify different clusters of patients according to MET
expression levels. The group with very-high MET
mRNA (3.5%) comprised a majority of males, former,
or current smokers with a median age of 58 years.
Interestingly, very-high MET mRNA expression clo-
sely correlated with MET gene amplification by NGS
or FISH and was mutually exclusive with METDex14.
Therefore, it is not surprising that the phenotype of
the patients with very-high MET mRNA agrees with
the characteristics previously reported in patients with
high MET amplification (defined as FISH gene copy
number, GCN ≥ 6 or ≥ 10) [16,17,39,40]. Further-
more, all the five very-high MET mRNA cases treated
with MET inhibitors achieved partial responses; the
majority of case baseline (7/9) did not harbor any
detectable driver. In contrast, the cohort of patients
with mod-elevated MET mRNA expression did not
correlate with any specific phenotype, being distributed
Fig. 4. Heatmap displaying samples with mod-elevated levels of MET mRNA expression by nCounter (n = 36). Corresponding results for
METDex14 (nC) RT–PCR, MET mutations (NGS), copy number alterations (FISH or NGS), immunohistochemistry (IHC), and other co-
occurring driver alterations are also shown. Patient numbers are shown in the top row. FISH, fluorescence in situ hybridization; GCN, gene
copy number; HS, histoscore; IHC, immunohistochemistry; Mod, moderate; N/A nonavailable data; nC, nCounter; NGS, next-generation
sequencing; RT–PCR, reverse transcription polymerase chain reaction.
358 Molecular Oncology 15 (2021) 350–363 ª 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
MET in advanced non-small cell lung cancer C. Aguado et al.
independently of gender and smoking habits, and
known drivers were detected in most cases. Although
the biological oncogenic significance of MET amplifi-
cation in NSCLC has been controversial [3,41], our
results endorse the concept of MET being a true driver
in patients with very-high expression mRNA levels. In
contrast, we believe that MET is unlikely to play a
clinically relevant role in tumors with mod-elevated
expression levels.
Several trials have recently evaluated the efficacy of
MET-TKIs in METΔex14-positive NSCLC. Overall
response rates of 32% have been reported for crizotinib,
a nonselective inhibitor, compared to 46–68% and 40–
55% in first or subsequent lines for the selective inhibi-
tors capmatinib, tepotinib, and savolitinib [11,13,14]. In
contrast, the results obtained so far in trials enrolling
MET-amplified patients are significantly worse, with
overall response rate (ORR) 20–47%
[16,17,20,39,40,42]. It is unclear whether the variety of
responses observed in trials of MET-TKIs may partly
underlie a heterogeneous disease population with dis-
tinct sensitivities to MET-TKIs and/or be a
consequence of the different thresholds, methodologies,
and scoring systems (MET/CEP7 ratios or GCN) that
have been used as eligibility criteria.
Our study can shed some light on this relevant issue,
and the characterization of MET expression levels in
NSCLC here presented provides a unique opportunity
to advance in the understanding of the processes
underlying MET biology. For instance, our RNA-
based assessment allowed the identification of amplifi-
cation-negative tumors with very-high MET expression
levels and also the relatively infrequent cases with gene
amplification that did not express MET mRNA.
Remarkably, one of the patients with very-high MET
mRNA levels but negative by FISH (using the two
usual cutoff values) was treated with a MET inhibitor
achieving a partial response. These observations sug-
gest that FISH positivity might be capturing a hetero-
geneous group regarding dependence on aberrant
MET signaling and that RNA-based techniques could
improve the performance of FISH for patient selec-
tion. This, in turn, may help to explain the inferior
response rates observed with MET-TKIs in FISH-
Fig. 5. Graphical summary of the results obtained with nCounter. The numbers and percentages of evaluable samples with different MET
mRNA expression are represented (N = 422). FISH, fluorescence in situ hybridization; METΔex14, MET exon 14 skipping mutation; Mod,
moderately; TKI, tyrosine kinase inhibitor.
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amplified tumors. In order to improve outcomes to
MET inhibition in this setting, it would be important
to further investigate the efficacy of MET-TKI in
those tumors with gene amplification that do not
express MET mRNA, and the real clinical value of
high expression levels in amplification-negative tumors
where MET inhibition therapy could be considered.
Regarding METDex14, recent studies have suggested
that MET protein expression is required for clinical ben-
efit from MET-TKIs [43]. Interestingly, the only MET-
Dex14 patient in our cohort who exhibited stable disease
to MET-targeted therapy had low levels of mRNA by
nCounter, whereas all treated patients with mod-ele-
vated levels had partial responses. Whether mRNA
expression levels can assist to predict outcome in
patients with METDex14 is currently unknown but also
merits further investigation. One of the limitations of
our study derives from the fact that MET is known to
be expressed not only in tumor cells but also in normal
epithelial [44], dendritic, and other immune cells [45]. In
consequence, particularly in cases with important
stroma and/or inflammatory component, the mRNA
expression levels obtained by nCounter might reflect the
level of MET expression in the whole tumor rather than
only in cancer cells. However, the good agreement
observed between MET mRNA levels by nCounter and
MET IHC staining in tumor cells indicated that, in most
samples, the contribution of noncancer components to
the nCounter results was not significant.
5. Conclusions
We have comprehensively characterized MET in a large
cohort of advanced NSCLC and have validated the use
of nCounter to identify METDex14 in this malignancy.
Our work also provides useful insights into the biology
of MET as a driver in NSCLC, supporting MET very-
high mRNA expression as a surrogate of amplification,
and suggesting the relevance of MET mRNA levels in
patients responding to MET-TKIs. Our results support
the use of mRNA-based techniques for multiplex, accu-
rate, and reliable assessment of MET alterations in
order to select patients for MET-targeted therapies.
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